Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011)
130 patients around the world
Available in Chile
Merck Sharp & Dohme LLC
1Research sites
130Patients around the world
This study is for people with
Gastrointestinal Cancer
Requirements for the patient
From 18 Years
All Gender
Medical requirements
Has one of the following cancers.
Unresectable or metastatic colorectal cancer.
Advanced and/or unresectable biliary tract cancer (BTC).
Hepatocellular carcinoma (HCC) not amenable to locoregional therapy.
Has received prior therapy for the cancer.
Has recovered from any side effects due to previous cancer treatment.
Has a history of (noninfectious) interstitial lung disease (ILD)/pneumonitis that required steroids, has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at Screening.
Has clinically severe respiratory compromise (based on the investigator's assessment) resulting from intercurrent pulmonary illnesses.
Has clinically significant corneal disease.
Has uncontrolled, significant cardiovascular disease or cerebrovascular disease.
Sites
Centro de Oncología de Precisión
Recruiting
Santiago, Región Metropolitana de Santiago, 7560908
